Cited 0 times in Scipus Cited Count

Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma

DC Field Value Language
dc.contributor.authorLee, J-
dc.contributor.authorHa, EJ-
dc.contributor.authorRoh, J-
dc.contributor.authorKim, HK-
dc.date.accessioned2023-01-05T03:03:47Z-
dc.date.available2023-01-05T03:03:47Z-
dc.date.issued2021-
dc.identifier.issn0039-6060-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23775-
dc.description.abstractBackground: The management of papillary thyroid microcarcinomas with TERT ± BRAF V600E mutations remains controversial owing to their potential associations with tumor aggressiveness. This study evaluated the clinical implications of these mutations in management of patients with papillary thyroid microcarcinomas. Methods: Between June 2019 and October 2020, surgical specimens from 504 consecutive patients with papillary thyroid microcarcinomas were obtained at a tertiary hospital. The mutation statuses of TERT promoter and BRAF V600E were assessed by polymerase chain reaction. The prevalence and relationships of TERT ± BRAF V600E mutations with clinical, radiological, and pathological characteristics were evaluated. Results: Of 504 patients with papillary thyroid microcarcinomas, TERT ± BRAF V600E mutations were found in 3.2% (16/504). Of these 16 patients, 93.8% (15/16) of papillary thyroid microcarcinomas with TERT promoter mutations also harbored BRAF V600E mutations. Correlation analysis showed that TERT ± BRAF V600E mutations were not associated with aggressive clinical, radiological, or pathological features (P > .05). The presence of lymph node metastasis was not associated with mutation status (P = .834). Conclusion: TERT ± BRAF V600E mutations in patients with papillary thyroid microcarcinomas are not associated with any unfavorable clinicopathological features, including lymph node metastasis status.-
dc.language.isoen-
dc.subject.MESHCarcinoma, Papillary-
dc.subject.MESHCombined Modality Therapy-
dc.subject.MESHDisease Management-
dc.subject.MESHDNA Mutational Analysis-
dc.subject.MESHDNA, Neoplasm-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMorbidity-
dc.subject.MESHMutation-
dc.subject.MESHPromoter Regions, Genetic-
dc.subject.MESHProto-Oncogene Proteins B-raf-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment-
dc.subject.MESHRisk Factors-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTelomerase-
dc.subject.MESHThyroid Neoplasms-
dc.titlePresence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma-
dc.typeArticle-
dc.identifier.pmid33952391-
dc.contributor.affiliatedAuthorLee, J-
dc.contributor.affiliatedAuthorHa, EJ-
dc.contributor.affiliatedAuthorRoh, J-
dc.contributor.affiliatedAuthorKim, HK-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.surg.2021.03.056-
dc.citation.titleSurgery-
dc.citation.volume170-
dc.citation.number3-
dc.citation.date2021-
dc.citation.startPage743-
dc.citation.endPage747-
dc.identifier.bibliographicCitationSurgery, 170(3). : 743-747, 2021-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1532-7361-
dc.relation.journalidJ000396060-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Radiology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse